Drug Target for Cancer: B7-H4

Drug Targets for Cancer: B7-H4 and Cancer

B7-H4 (B7S1 or B7X) is a member of B7 family and inhibits the T cell mediated response by inhibiting T cell proliferation, activation, and cytokine production. B7-H4 also inhibits the innate immune response by suppressing the growth of immunocyte, thereby allowing cancers to avoid immunologic surveillance. B7-H4 was overexpressed in many cancers, including non–small cell lung cancer, melanoma, breast cancer, ovary cancer, prostate cancer, esophagus cancer, stomach cancer, pancreas cancer, and kidney cancer, but not in normal tissues. B7-H4 may be associated with cancer progression and can be a prognostic marker in some cancers.

Drug Targets for Cancer: B7-H4 related Products

Other vital drug targets for cancer like B7-H4:

Drug Targets for Cancer: B7-H4 Related Reference

Qian Y, Sang Y, Wang F X C, et al. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases[J]. Oncotarget, 2016, 7(44): 72242-72249.

Drug Targets for Cancer: B7-H4 Related Information